{"result": "{\n    \"title\": \"Breast Cancer Treatment Community\",\n    \"summary\": \"The community revolves around breast cancer treatment, with key entities including neratinib, Lancet Oncol, HER2, and ExteNET. These entities are related through their roles in breast cancer treatment, with neratinib being a medication used in various treatment settings, Lancet Oncol being a medical research journal, HER2 being a protein receptor, and ExteNET being a clinical trial.\",\n    \"rating\": 7.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant medical advancements and treatment options in the breast cancer community.\",\n    \"findings\": [\n        {\n            \"summary\": \"Neratinib's role in breast cancer treatment\",\n            \"explanation\": \"Neratinib is a medication used in various treatment settings for breast cancer, including adjuvant therapy for high-risk recurrent disease and treatment of HER2-positive breast cancer. [Data: Entities (200), Relationships (75, 133, 134)]\"\n        },\n        {\n            \"summary\": \"Lancet Oncol's significance in breast cancer research\",\n            \"explanation\": \"Lancet Oncol is a medical research journal that has published numerous studies on breast cancer, including research on adjuvant bevacizumab-containing therapy and neoadjuvant and adjuvant trastuzumab. [Data: Entities (665), Relationships (246, 527)]\"\n        },\n        {\n            \"summary\": \"HER2's importance in breast cancer treatment\",\n            \"explanation\": \"HER2 is a protein receptor that is often overexpressed in breast cancer, making it a target for treatment. Its overexpression is associated with poor prognosis, and its status is an important factor in determining the effectiveness of breast cancer treatment. [Data: Entities (70), Relationships (131, 132, 135)]\"\n        },\n        {\n            \"summary\": \"ExteNET's contribution to breast cancer research\",\n            \"explanation\": \"ExteNET is a clinical trial that studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population. [Data: Entities (202), Relationships (254, 253)]\"\n        },\n        {\n            \"summary\": \"T-DM1's role in breast cancer treatment\",\n            \"explanation\": \"T-DM1 is a type of targeted therapy that was studied in the KATERINE trial, which recommended its use as adjuvant therapy in patients with HER2+ breast cancer. [Data: Entities (198), Relationships (252, 253)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n200,\"\"\"NERATINIB\"\"\",\"Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.\",8\r\n665,\"\"\"LANCET ONCOL\"\"\",\"Here is a comprehensive summary of the data:\n\n\"\"Lancet Oncol\"\" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, \"\"Lancet Oncol\"\" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.\",3\r\n70,\"\"\"HER2\"\"\",\"Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.\",6\r\n202,\"\"\"EXTENET\"\"\",\"Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.\",2\r\n198,\"\"\"KATERINE TRIAL\"\"\",\"Here is a comprehensive summary of the data:\n\nThe \"\"KATERINE TRIAL\"\" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial's findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.\",2\r\n781,\"\"\"HARVEY VJ\"\"\",\"\"\"Harvey VJ is an author of a medical study.\"\"\",1\r\n201,\"\"\"HER4\"\"\",\"\"\"HER4 is a protein that is targeted by neratinib.\"\"\",1\r\n69,\"\"\"HR\"\"\",\"Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n75,\"\"\"IBC\"\"\",\"\"\"NERATINIB\"\"\",\"\"\"Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.\"\"\",62\r\n246,\"\"\"GEPARQUINTO\"\"\",\"\"\"LANCET ONCOL\"\"\",\"\"\"GeparQuinto is published in Lancet Oncol.\"\"\",24\r\n131,\"\"\"HER2\"\"\",\"\"\"TRASTUZUMAB\"\"\",\"\"\"Trastuzumab is targeted towards HER2+ disease, including IBC.\"\"\",21\r\n132,\"\"\"HER2\"\"\",\"\"\"LAPATINIB\"\"\",\"\"\"Lapatinib blocks intracellular HER2, which is a target for cancer treatment.\"\"\",18\r\n256,\"\"\"NERATINIB\"\"\",\"\"\"PATIENT\"\"\",\"\"\"Neratinib is offered as a treatment option for patients.\"\"\",18\r\n135,\"\"\"HER2\"\"\",\"\"\"PATIENT\"\"\",\"\"\"Patient's HER2 status is used to determine treatment options.\"\"\",16\r\n527,\"\"\"PIERGA JY\"\"\",\"\"\"LANCET ONCOL\"\"\",\"\"\"Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.\"\"\",16\r\n133,\"\"\"HER2\"\"\",\"\"\"NERATINIB\"\"\",\"\"\"Neratinib targets HER2, a protein involved in breast cancer.\"\"\",14\r\n134,\"\"\"HER2\"\"\",\"\"\"PD-L1\"\"\",\"\"\"HER2 is associated with PD-L1 expression in breast cancer.\"\"\",13\r\n157,\"\"\"EGFR\"\"\",\"\"\"NERATINIB\"\"\",\"\"\"Neratinib targets EGFR, a protein involved in breast cancer.\"\"\",12\r\n254,\"\"\"NERATINIB\"\"\",\"\"\"EXTENET\"\"\",\"\"\"Neratinib was studied in the ExteNET clinical trial.\"\"\",10\r\n253,\"\"\"KATERINE TRIAL\"\"\",\"\"\"NERATINIB\"\"\",\"\"\"The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.\"\"\",10\r\n257,\"\"\"NERATINIB\"\"\",\"\"\"HARVEY VJ\"\"\",\"\"\"Harvey VJ is involved in the development of Neratinib.\"\"\",9\r\n255,\"\"\"NERATINIB\"\"\",\"\"\"HER4\"\"\",\"\"\"Neratinib targets HER4, a protein involved in breast cancer.\"\"\",9\r\n130,\"\"\"HR\"\"\",\"\"\"HER2\"\"\",\"\"\"HER2 and HR are protein receptors that are targets for breast cancer treatment.\"\"\",7\r\n258,\"\"\"EXTENET\"\"\",\"\"\"LANCET ONCOL\"\"\",\"\"\"ExteNET is published in Lancet Oncol.\"\"\",5\r\n252,\"\"\"T-DM1\"\"\",\"\"\"KATERINE TRIAL\"\"\",\"\"\"The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.\"\"\",5\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}